Hyperion DeFi, Inc., a DeFi company, engages in building on Hyperliquid. It operates through two segments: Ophthalmic Technology and Digital Assets. The company focuses on the long-term strategic treasury of HYPE tokens to provide simplified exposure to the Hyperliquid blockchain ecosystem. It is also developing the Optejet User Filled Device to work with various topical ophthalmic liquids, including artificial tears and lens rewetting products. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025. Hyperion DeFi, Inc. was founded in 2014 and is based in Dallas, Texas.…
Hyperion DeFi, Inc. Q3 2026 Earnings Call Summary
Hyperion DeFi (NASDAQ: HYPD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 9 employees.
The shares were at 2.080 USD on 20 November 2026, down 67.7% over 52 weeks. Its 52-week range is 2.010 USD to 6.300 USD: the price is 67.0% below the high and 3.5% above the low.
Its market capitalisation is 31.72M USD.
Hyperion DeFi reports return on equity of -110.4% and revenue up 167.9% year over year.
It holds more cash than debt, a net cash position of 5.91M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. The next earnings report is expected on 25 March 2027.